Michael Andreeff

Professor

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Michael Andreeff is a Professor at The University of Texas MD Anderson Cancer Center, USA. His research focuses on the mechanisms of drug resistance in cancer, particularly through the study of GD3 synthase and BCL-2 pathways in breast cancer and acute myeloid leukemia. He has published extensively on therapeutic targets in hematological malignancies and the role of microRNAs in chronic myeloid leukemia.

Articles (9)

Year:

2025

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (7)

Pierluigi Gasparini

Conjoint Senior Lecturer

University of Newcastle Australia

AUSTRALIA

View details

Jacqueline Boultwood

University of Oxford

UNITED KINGDOM

View details

Carlo M. Croce

Ohio State University

UNITED STATES

View details

Bing Carter

professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Andrea Pellagatti

University of Oxford

UNITED KINGDOM

View details

Lauren Ostermann

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Rasoul Pourebrahim

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael Andreeff

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

GD3 synthase drives resistance to p53-induced apoptosis in breast cancer by modulating mitochondrial function

Mdm2/p53 levels in bone marrow mesenchymal stromal cells are essential for maintaining the hematopoietic niche in response to DNA damage

Ganglioside GD2: a novel therapeutic target in triple‐negative breast cancer

BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome

Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML

Therapeutic implications of menin inhibition in acute leukemias

Loss of expression of both miR-15/16 loci in CML transition to blast crisis

Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia

Clinical value of event-free survival in acute myeloid leukemia

Collaborators (7)

Pierluigi Gasparini

Jacqueline Boultwood

Carlo M. Croce

Bing Carter

Andrea Pellagatti

Lauren Ostermann

Rasoul Pourebrahim

Make your next move.